Recent Updates
Recently added Catalysts

1 µg CoV2 SAM

Phase 1

Virus Diseases | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Aug 24, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment10

FDA Designations

No designations recorded

Clinical trial landscape

1 µg CoV2 SAM · 1 trial · 1 indication

Phase 1 1
NCT04758962A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy AdultsVirus Diseases
COMPLETED10 Analytics
PHASE1COMPLETED
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
Virus DiseasesUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Solicited Administration Site Adverse Events After Each Vaccination
Within 7 days post each vaccination (vaccination at Day 1 and Day 31)

The solicited administration site adverse events assessed were pain, redness and swelling.

Number of Participants With Solicited Systemic Adverse Events After Each Vaccination
Within 7 days post each vaccination (vaccination at Day 1 and Day 31)

The solicited systemic events assessed were abdominal pain, arthralgia, diarrhea, fatigue, fever, headache, myalgia, nausea, vomiting. Fever is defined as temperature ≥38.0°Celsius (C)/100.4°Fahrenheit (F) regardless the location of measurement.

Number of Participants With Unsolicited Adverse Events (AEs) After Each Vaccination
Within 30 days post each vaccination (vaccination at Day 1 and Day 31)

An unsolicited AE is defined as an AE that was not included in a list of solicited events using a Participant eDiary, or any solicited event with onset after the 7-day period post each vaccination.

Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 2 Compared With Baseline (Day 1)
Day 2 compared to baseline (Day 1)

The hematological and biochemical laboratory parameters assessed include alanine aminotransferase (ALT),alkaline phosphatase (ALP),aspartate aminotransferase (AST),bilirubin,creatinine,urea nitrogen,eosinophils,erythrocytes,hemoglobin,leukocytes,lymphocytes,neutrophils,partial thromboplastin time (PTT) and platelets. Categories reported for each parameter when comparing Day 1 baseline and post-baseline hematological and biochemical laboratory results are defined as follows:\<range at baseline \[Day 1\]\>, \<range at post-baseline time point\> for example, Below-Within, where each range is classified as below, within, or above the applicable laboratory reference range. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.

Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 8 Compared With Baseline (Day 1)
Day 8 compared to baseline (Day 1)

The hematological and biochemical laboratory parameters assessed include ALT, ALP, AST, bilirubin, creatinine, urea nitrogen, eosinophils, erythrocytes, hemoglobin, leukocytes, lymphocytes, neutrophils, PTT and platelets. Categories reported for each parameter when comparing Day 1 (baseline) and post-baseline hematological and biochemical laboratory results are defined as follows: \<range at baseline \[Day 1\]\>, \<range at post-baseline time point\> for example, Below-Within, where each range is classified as below, within, or above the applicable laboratory reference range. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter; Unknown = No results are available for the specified visit and laboratory parameter.

Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 31 Compared With Baseline (Day 1)
Day 31 compared to baseline (Day 1)

The hematological and biochemical laboratory parameters assessed include ALT, ALP, AST, bilirubin, creatinine, urea nitrogen, eosinophils, erythrocytes, hemoglobin, leukocytes, lymphocytes, neutrophils, PTT and platelets. Categories reported for each parameter when comparing Day 1 (baseline) and post-baseline hematological and biochemical laboratory results are defined as follows: \<range at baseline \[Day 1\]\>, \<range at post-baseline time point\> for example, Below-Within, where each range is classified as below, within, or above the applicable laboratory reference range. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter; Unknown = No results are available for the specified visit and laboratory parameter.

Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 32 Compared With Baseline (Day 1)
Day 32 compared to baseline (Day 1)

The hematological and biochemical laboratory parameters assessed include ALT, ALP, AST, bilirubin, creatinine, urea nitrogen, eosinophils, erythrocytes, hemoglobin, leukocytes, lymphocytes, neutrophils, PTT and platelets. Categories reported for each parameter when comparing Day 1 (baseline) and post-baseline hematological and biochemical laboratory results are defined as follows: \<range at baseline \[Day 1\]\>, \<range at post-baseline time point\> for example, Below-Within, where each range is classified as below, within, or above the applicable laboratory reference range. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter; Unknown = No results are available for the specified visit and laboratory parameter.

Number of Participants With Hematological and Biochemical Laboratory Abnormalities at Day 38 Compared With Baseline (Day 1)
Day 38 compared to baseline (Day 1)

The hematological and biochemical laboratory parameters assessed include ALT, ALP, AST, bilirubin, creatinine, urea nitrogen, eosinophils, erythrocytes, hemoglobin, leukocytes, lymphocytes, neutrophils, PTT and platelets. Categories reported for each parameter when comparing Day 1 (baseline) and post-baseline hematological and biochemical laboratory results are defined as follows: \<range at baseline \[Day 1\]\>, \<range at post-baseline time point\> for example, Below-Within, where each range is classified as below, within, or above the applicable laboratory reference range. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter; Unknown = No results are available for the specified visit and laboratory parameter.

Number of Participants With Medically-attended AEs (MAEs) From Day 1 to Day 61
Day 1 to Day 61

A medically attended adverse event (MAE) is defined as an AE for which the participant received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (i.e., nurse practitioner or physician assistant or medical doctor) for any reason.

Number of Participants With Serious AEs (SAEs) From Day 1 to Day 61
Day 1 to Day 61

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgment.

Number of Participants With Adverse Events of Special Interest (AESIs) [Potential Immune-mediated Diseases (pIMDs) and COVID-19 Cases) From Day 1 to Day 61
Day 1 to Day 61

AESIs assessed include pIMDs and COVID-19 cases. pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any suspected, probable or confirmed case of COVID-19 was reported.

Secondary Endpoints

Number of Participants With MAEs, SAEs and AESIs (pIMDs and COVID-19 Cases) From Day 1 up to Day 391
Day 1 to Day 391
Percentage of Participants With Anti-Spike (S) Immunoglobulin G (IgG) Antibody Concentrations at Day 1, Day 31 and Day 61
At pre-vaccination on Day 1 and Day 31, and at Day 61
Number of Participants With Anti-Nucleocapsid (N) IgG Antibody Concentrations at Day 1, Day 31 and Day 61
At pre-vaccination on Day 1 and Day 31, and at Day 61
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposePREVENTION

Treatment Arms

ArmTypeDescription
CoV-2 SAM [LNP] GroupEXPERIMENTALParticipants received two 1-microgram (µg) doses of Coronavirus-2 Spike self-amplifying mRNA lipid nanoparticle (CoV-2 SAM \[LNP\]) vaccine, one at Day 1 and one at Day 31.

Interventions

NameTypeDescription
1 µg CoV2 SAM (LNP)BIOLOGICAL2 doses of 1 µg CoV2 SAM (LNP) vaccine in 0,1-month schedule, administered IM in the deltoid of the non-dominant arm.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol. * Written or thumb printed informed consent obtained from the participant prior to performance of any study specific procedure. * Healthy participants as establishe...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about 1 µg CoV2 SAM

What is 1 µg CoV2 SAM used for?

1 µg CoV2 SAM is an investigational vaccine being studied for the prevention of virus diseases, including COVID-19. It is currently in Phase 1 clinical development and has not been approved for use. The vaccine is designed to elicit an immune response against the virus in healthy adults.

Who makes 1 µg CoV2 SAM?

1 µg CoV2 SAM is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and immunogenicity of this vaccine candidate.

What phase is 1 µg CoV2 SAM in?

1 µg CoV2 SAM is in Phase 1 clinical development. It is an investigational vaccine that has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine remains under investigation for its safety and immune response profile.

What clinical trials is 1 µg CoV2 SAM in?

1 µg CoV2 SAM has been studied in one completed Phase 1 clinical trial with the identifier NCT04758962. This trial evaluated the safety of and immune response to varying doses of the vaccine against COVID-19 in healthy adults in the United States. The trial enrolled 10 participants.

How does 1 µg CoV2 SAM work?

1 µg CoV2 SAM is a vaccine candidate that works by presenting a piece of the virus to the immune system to trigger an immune response. It is designed to teach the body to recognize and fight the virus that causes COVID-19, potentially providing protection against infection.